title: Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults.
abstract: OBJECTIVE
  We evaluated the association of combined use of antidepressants and statins and the risk of new-onset diabetes among high-risk adults.
  
  
  METHODS
  We used a retrospective, observational, longitudinal design among adults (age ≥ 22 years) who were diabetes free at baseline and had reported hypertension or hyperlipidemia or heart disease. We used data were from 2004 to 2009 Medical Expenditure Panel Survey and identified from self-reported diabetes or insulin use. We categorized antidepressants and statins use into four groups: antidepressants only, statins only, combined use of antidepressants and statins (antidepressants-statins), and neither antidepressant nor statins. We conducted chi-square and multivariable logistic regressions to examine the association between use of antidepressants-statins and new-onset diabetes after controlling for demographic and economic characteristics, health-status, access to care, presence of depression, and lifestyle risk factors.
  
  
  RESULTS
  In our study sample, 9.3% used antidepressants only, 10.7% used statins only and 2.4% adults reported use of antidepressants-statins. Nearly 2% of the study sample reported new-onset diabetes. In unadjusted analyses, significantly higher proportion of adults using antidepressants-statins (3.2%) reported new-onset diabetes compared to those using neither antidepressants nor statins (1.1%). However, after controlling for all other variables in multivariable regression we did not observe a statistically significant association between use of antidepressants-statins and new-onset diabetes.
  
  
  CONCLUSIONS
  Our study results do not suggest that use of antidepressants-statins may increase the risk of new-onset diabetes. Future research needs to examine this relationship with specific combinations of these drug classes and using longer follow up periods.
authors: Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA. Electronic address: rbhattacharya@hsc.wvu.edu.
authors: Rituparna
authors: R
authors: Bhattacharya
authors: Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA.
authors: Mayank
authors: M
authors: Ajmera
authors: Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA.
authors: Sandipan
authors: S
authors: Bhattacharjee
authors: Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA.
authors: Usha
authors: U
authors: Sambamoorthi
mesh_terms: D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects*; D003863:Depression / Q000188:drug therapy*; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000378:metabolism; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D006973:Hypertension / Q000188:drug therapy*; D008019:Life Style; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012107:Research Design; D012189:Retrospective Studies; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Antidepressants; New-onset diabetes; Statins